GSK3 inhibition reduced TDP-43 toxicity in neuron models
Original source
Inhibiting Glycogen Synthase Kinase 3 Suppresses TDP-43-Mediated Neurotoxicity in a Caspase-Dependent Manner. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Studied in
- Human, Mouse, Cells
Related topics
In a primary research study, inhibiting glycogen synthase kinase 3 (GSK3) reduced toxic, truncated forms of TDP-43 and improved neuronal survival. The effects were seen in rodent neurons and human induced pluripotent stem cell-derived cortical neurons, and involved caspase-dependent TDP-43 cleavage.
Why this matters
The findings identify a possible treatment strategy for TDP-43-related amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). However, the work was conducted in laboratory neuron models, so it does not yet show that GSK3 inhibition benefits people with ALS or FTD or change current treatment.
Limitations and context
This was laboratory research using cell and neuron models, not a clinical trial. The study did not establish safety or effectiveness in people, and further research would be needed before testing whether GSK3 inhibition can treat ALS or FTD.